Je was op zoek naar: laropiprant (Deens - Engels)

laropiprant:
laropiprant:

nicotinsyre og laropiprant.
what pelzont contains • the active substances are nicotinic acid and laropiprant.

andre lægemidlers indvirkning på laropiprant
effects of other medicinal products on laropiprant

2 gange ved flergangsdosering af laropiprant.
however, the plasma concentration of a metabolite of midazolam, 1'-hydroxymidazolam, was increased approximately 2-fold with multiple doses of laropiprant.

aktive stoffer: nicotinsyre og laropiprant.
the active substances are nicotinic acid and laropiprant.

dyreforsøg har vist udskillelse af laropiprant i mælken.
animal studies have shown excretion of laropiprant in milk.

det er ukendt, om laropiprant udskilles i modermælk.
it is unknown whether laropiprant is excreted in human breast milk.

laropiprant forventes ikke at hæmme produktionen af prostaglandiner.
laropiprant is not expected to inhibit the production of prostaglandins.

laropiprant laropiprants indvirkning på andre lægemidler midazolam:
laropiprant effects of laropiprant on other medicinal products midazolam:

laropiprant: dosisjustering er ikke nødvendig på basis af køn.
laropiprant: no dose adjustment is necessary based on gender.

andre lægemidlers indvirkning på laropiprant cyp3a4- hæmmer:
effects of other medicinal products on laropiprant cyp3a4 inhibitor:

laropiprant blokerer de receptorer, som pgd2 normalt binder sig til.
laropiprant blocks the receptors to which pgd2 normally attaches.

derfor er laropiprant ikke en inducer eller hæmmer af cyp3a4.
therefore, laropiprant is not an inducer or inhibitor of cyp3a4.

laropiprant der foreligger ingen data for anvendelsen af laropiprant til gravide.
laropiprant there are no data from the use of laropiprant in pregnant women.

dyreforsøg har vist føtal udviklingstoksicitet ved høje doser laropiprant (se pkt.
studies in animals have shown foetal developmental toxicity at high doses of laropiprant (see section 5.3).

laropiprant var ikke mutagent eller klastogent i en række af genetiske toksilogiundersøgelser.
laropiprant was not mutagenic or clastogenic in a series of genetic toxicology studies.

de to aktive stoffer i pelzont, nikotinsyre og laropiprant, har forskellige virkemåder.
the two active substances in pelzont, nicotinic acid and laropiprant, have different modes of action.

pelzont 1.000 mg/20 mg tabletter med modificeret udløsning nicotinsyre/laropiprant
pelzont 1,000 mg/20 mg modified-release tablets nicotinic acid/laropiprant

når patienten tager tabletten, frigives laropiprant først til blodbanen og blokerer pgd2-receptorerne.
when the patient takes the tablet, laropiprant is released first into the bloodstream and blocks the pgd2 receptors.

laropiprant elimineres primært via acylglucuronidering efterfulgt af glucuronidudskillelse i fæces (via galden) og urin.
laropiprant is eliminated primarily via acyl glucuronidation, followed by excretion of the glucuronide in faeces (via bile) and urine.